UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Early Detection of Ovarian Cancer in Samples Pre-Diagnosis Using CA125 and MALDI-MS Peaks

Timms, JF; Menon, U; Devetyarov, D; Tiss, A; Camuzeaux, S; Mccurrie, K; Nouretdinov, I; ... Jacobs, I; + view all (2011) Early Detection of Ovarian Cancer in Samples Pre-Diagnosis Using CA125 and MALDI-MS Peaks. Cancer Genomics & Proteomics , 8 (6) 289 - 305. Green open access

[thumbnail of Camuzeaux_Timms et al CGP submission revised with Figures.pdf]
Preview
Text
Camuzeaux_Timms et al CGP submission revised with Figures.pdf

Download (556kB) | Preview

Abstract

Aim: A nested case-control discovery study was undertaken 10 test whether information within the serum peptidome can improve on the utility of CA125 for early ovarian cancer detection. Materials and Methods: High-throughput matrix-assisted laser desorption ionisation mass spectrometry (MALDI-MS) was used to profile 295 serum samples from women pre-dating their ovarian cancer diagnosis and from 585 matched control samples. Classification rules incorporating CA125 and MS peak intensities were tested for discriminating ability. Results: Two peaks were found which in combination with CA125 discriminated cases from controls up to 15 and 11 months before diagnosis, respectively, and earlier than using CA125 alone. One peak was identified as connective tissue-activating peptide III (CTAPIII), whilst the other was putatively identified as platelet factor 4 (PF4). ELISA data supported the down-regulation of PF4 in early cancer cases. Conclusion: Serum peptide information with CA125 improves lead time for early detection of ovarian cancer. The candidate markers are platelet-derived chemokines, suggesting a link between platelet function and tumour development.

Type: Article
Title: Early Detection of Ovarian Cancer in Samples Pre-Diagnosis Using CA125 and MALDI-MS Peaks
Open access status: An open access version is available from UCL Discovery
Publisher version: http://cgp.iiarjournals.org/content/8/6/289.long
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: MALDI MS serum profiling, ovarian cancer, biomarkers, early diagnosis, CA125, connective tissue-activating peptide III (CTAPIII), platelet factor 4 (PF4).
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health > Womens Cancer
URI: https://discovery.ucl.ac.uk/id/eprint/1331813
Downloads since deposit
38Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item